Abatacept Promotes Regulatory B Cell Functions, Enhancing Their Ability to Reduce the Th1 Response in Rheumatoid Arthritis Patients through the Production of IL-10 and TGF-β

2021 ◽  
pp. ji2000455
Author(s):  
Guillermo Carvajal Alegria ◽  
Divi Cornec ◽  
Alain Saraux ◽  
Valérie Devauchelle-Pensec ◽  
Christophe Jamin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
B Cell ◽  
Regulatory B Cell ◽  
Th1 Response ◽  
Cell Functions

Vasoactive intestinal peptide alleviates food allergy via restoring regulatory B cell functions

Immunobiology ◽  
2019 ◽  
Vol 224 (6) ◽  
pp. 804-810 ◽  
Author(s):  
Hao-Tao Zeng ◽  
Miao Zhao ◽  
Shao-Bo Yang ◽  
Huang Huang ◽  
Xiao-Rui Geng ◽  
...  
Keyword(s):  
Food Allergy ◽  
B Cell ◽  
Vasoactive Intestinal Peptide ◽  
Regulatory B Cell ◽  
Cell Functions

AB0088 Regulatory b cell is negatively associated with disease activity in rheumatoid arthritis

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A812.3-A812
Author(s):  
I. S. Yoo ◽  
S. T. Song ◽  
H. J. Lee ◽  
J. Kim ◽  
S. W. Kang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
B Cell ◽  
Regulatory B Cell ◽  
Negatively Associated

scholarly journals JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis

2021 ◽  
Vol 7 ◽  
Author(s):  
Rita A. Moura ◽  
João Eurico Fonseca
Keyword(s):  
Rheumatoid Arthritis ◽  
B Cells ◽  
Immune Responses ◽  
B Cell ◽  
Janus Kinase ◽  
Sustained Remission ◽  
Close Monitoring ◽  
Jak Inhibitors ◽  
Autoantibody Production ◽  
Cell Functions

Rheumatoid arthritis (RA) is a chronic, systemic immune-mediated inflammatory disease that can lead to joint destruction, functional disability and substantial comorbidity due to the involvement of multiple organs and systems. B cells have several important roles in RA pathogenesis, namely through autoantibody production, antigen presentation, T cell activation, cytokine release and ectopic lymphoid neogenesis. The success of B cell depletion therapy with rituximab, a monoclonal antibody directed against CD20 expressed by B cells, has further supported B cell intervention in RA development. Despite the efficacy of synthetic and biologic disease modifying anti-rheumatic drugs (DMARDs) in the treatment of RA, few patients reach sustained remission and refractory disease is a concern that needs critical evaluation and close monitoring. Janus kinase (JAK) inhibitors or JAKi are a new class of oral medications recently approved for the treatment of RA. JAK inhibitors suppress the activity of one or more of the JAK family of tyrosine kinases, thus interfering with the JAK-Signal Transducer and Activator of Transcription (STAT) signaling pathway. To date, there are five JAK inhibitors (tofacitinib, baricitinib, upadacitinib, peficitinib and filgotinib) approved in the USA, Europe and/ or Japan for RA treatment. Evidence from the literature indicates that JAK inhibitors interfere with B cell functions. In this review, the main results obtained in clinical trials, pharmacokinetic, in vitro and in vivo studies concerning the effects of JAK inhibitors on B cell immune responses in RA are summarized.

scholarly journals Glatiramer Acetate Stimulates Regulatory B Cell Functions

2019 ◽  
Vol 202 (7) ◽  
pp. 1970-1980 ◽  
Author(s):  
Kahina Amrouche ◽  
Jacques-Olivier Pers ◽  
Christophe Jamin
Keyword(s):  
B Cell ◽  
Glatiramer Acetate ◽  
Regulatory B Cell ◽  
Cell Functions
Sign in / Sign up

Export Citation Format

Share Document